Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Neuroestimulação não invasiva como ferramenta de diagnóstico e tratamento de doenças neurodegenerativas

29 de setembro de 2026 atualizado por: Eino Solje, Kuopio University Hospital

Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.

Visão geral do estudo

Descrição detalhada

Double blinded, sham-controlled, randomized trial on repeated transcranial alternating current brain stimulation (tACS) in neurodegenerative diseases. The investigators will evaluate whether a 4-times daily repeated stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with neurodegenerative diseases, including dementia with Lewy Bodies, Alzheimer's disease, idiopathic normal pressure hydrocephalus and Frontotemporal dementia.

Tipo de estudo

Intervencional

Inscrição (Estimado)

200

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Eino Solje, MD, PhD
  • Número de telefone: +358 17 713 311
  • E-mail: eino.solje@uef.fi

Locais de estudo

      • Kuopio, Finlândia
        • Recrutamento
        • Kuopio University Hospital
        • Contato:
          • Eino Solje

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Mild Cognitive Impairment due to Alzheimer's disease
  • Dementia with Lewy Bodies
  • Frontotemporal dementia
  • Idiopathic normal pressure hydrocephalus (iNPH)

Exclusion Criteria:

  • History of seizures
  • Pregnancy
  • Metal implants in the head (except dental fillings)
  • Electronic implants (i.e. pace-maker, implanted medical pump)
  • Age <18 years

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Real tACS

Four sessions (once a day, during four consecutive days) of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)

Single session of gamma tACS (40 Hz) over the superior parietal cortex

Comparador de Placebo: Sham tACS

Four sessions of sham tACS (once a day, during four consecutive days) over the superior parietal cortex (Precuneus)

Single session of gamma tACS (40 Hz) over the superior parietal cortex

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Changes in Rey Auditory Verbal Learning Test score
Prazo: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes.

The examiner reads aloud 15 unrelated words and the participant is asked to recall the words after each of the five trials. After a 15 minute delay, the participant is asked again to recall the words. The score ranges from 0 (worst performance) to 75 (best performance).

Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
Changes in Rey Auditory Verbal Learning Test, recognition
Prazo: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat.

After a 15 minute delay, the participant is asked to recognise the original 15 words intermixed with 31 distractor words. The score of the recognition part ranges from 0 (worst performance) to 46 (best performance).

Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention
Changes in orientation to time and place (MMSE questions 1-10)
Prazo: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

10 questions about the orientation. The score ranges from 0 (worse performance) to 10 (best performance).

Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
Changes in Trail Making A & B tests
Prazo: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention

TMT A & B tests. Time to perform set is recorded.

Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
Changes in INECO Frontal Screening test
Prazo: Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention

Test battery assessing frontal lobe functions. The score ranges from 0 (worse performance) to 30 (best performance)

Baseline (immediately before the intervention), immediately after the 4th intervention, 4 weeks after the last intervention
Changes in phonemic fluency
Prazo: Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Person is requested to provide as many words as possible starting with certain letter. The score is the sum of all acceptable words produced in one minute.

Baseline (immediately before the intervention), immediately after the first intervention, immediately after the 4th intervention, 4 weeks after the last intervention

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Change in SAI measurements
Prazo: Baseline (immediately before the intervention), immediately after the last intervention

By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic neurotransmission.

Baseline (immediately before the intervention), immediately after the last intervention
Change in SICI measurements
Prazo: Baseline (immediately before the intervention), immediately after the last intervention

By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short interval intracortical inhibition (SICI), which is a marker of gabaergic neurotransmission.

Baseline (immediately before the intervention), immediately after the last intervention
Change in ICF measurements
Prazo: Baseline (immediately before the intervention), immediately after the last intervention

By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on intracortical facilitation (ICF), which is a marker of glutamatergic neurotransmission.

Baseline (immediately before the intervention), immediately after the last intervention
Change in modified Frontal Behavioral Inventory (FBI-mod) score
Prazo: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

The modified Frontal Behavioral Inventory (FBI-mod) is used to assess behavioral symptoms associated with frontotemporal dysfunction. The questionnaire evaluates changes in behavioral and personality features. Higher scores indicate a greater severity of behavioral symptoms.

Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention
Change in Neuropsychiatric Inventory (NPI) score
Prazo: Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

The Neuropsychiatric Inventory (NPI) is used to assess neuropsychiatric symptoms, including their frequency and severity. Higher total scores indicate a greater burden of neuropsychiatric symptoms.

Baseline (immediately before the intervention), immediately after the last intervention, 4 weeks after the last intervention

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Eino Solje, MD, PhD, Kuopio University Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

21 de novembro de 2022

Conclusão Primária (Estimado)

1 de julho de 2032

Conclusão do estudo (Estimado)

1 de julho de 2032

Datas de inscrição no estudo

Enviado pela primeira vez

23 de março de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de abril de 2022

Primeira postagem (Real)

14 de abril de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

2 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

29 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Pseudonymized data upon request, according to Finnish national and EU GDPR regulations

Prazo de Compartilhamento de IPD

Data will be shared after the study completion indefinitely.

Critérios de acesso de compartilhamento IPD

Reasonable request

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever